Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
PubMed
18179625
DOI
10.1111/j.1751-1097.2007.00260.x
PII: PHP260
Knihovny.cz E-zdroje
- MeSH
- anthraceny MeSH
- antitumorózní látky terapeutické užití MeSH
- aplikace lokální MeSH
- bazocelulární karcinom farmakoterapie MeSH
- Bowenova nemoc farmakoterapie MeSH
- dospělí MeSH
- fotochemoterapie metody MeSH
- fytoterapie MeSH
- keratóza farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- molekulární struktura MeSH
- nádory kůže farmakoterapie MeSH
- perylen analogy a deriváty terapeutické užití MeSH
- pilotní projekty MeSH
- rostlinné přípravky terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- třezalka * chemie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- anthraceny MeSH
- antitumorózní látky MeSH
- hypericin MeSH Prohlížeč
- perylen MeSH
- rostlinné přípravky MeSH
Hypericin, the photoactive compound of Hypericum perforatum, is probably the most powerful photosensitizer found in nature. This compound has shown high potency in the photodynamic treatment of tumor cells. However, there is only limited knowledge regarding the photodynamic effect of hypericin on nonmelanoma skin cancer cells. The aim of this prospective study was to investigate the efficacy of photodynamic therapy with topical application of an extract of H. perforatum in actinic keratosis, basal cell carcinoma (BCC) and morbus Bowen (carcinoma in situ). The study was carried out on 34 patients--eight with actinic keratoses (AKs), 21 with BCC and five with Bowen's disease. The extract of H. perforatum was applied on the skin lesions under occlusion and that was followed by irradiation with 75 J cm(-2) of red light 2 h later. The treatment was performed weekly for 6 weeks on average. The percentage of complete clinical response was 50% for AKs, 28% in patients with superficial BCC and 40% in patients with Bowen's disease. There was only a partial remission seen in patients with nodular BCCs. A complete disappearance of tumor cells was found in the histologic preparation of 11% of patients with superficial BCCs and 80% in the patients with Bowen's disease. All patients complained of burning and pain sensations during irradiation. Although the results of this first clinical trial could be regarded as disappointing, there are still possibilities for improvement. Better preparation of the lesions, enhancement of hypericin delivery and other types of light exposure procedures could significantly improve the clinical outcomes of this relatively inexpensive treatment modality.
Citace poskytuje Crossref.org